The pharmaceutical quality revolution

Authors

  • Jordi Botet Glez. Tablas, 17, 5-1 08034 Barcelona Spain, Spain

DOI:

https://doi.org/10.15587/2313-8416.2016.58866

Keywords:

Continual improvement, Critical Process Parameter (CPP), Critical Quality Attribute (CQA), Knowledge management, Lifecycle, Pharmaceutical Quality System (PQS), Quality by design (QbD), Quality risk management, Quality Target Product Profile (QTPP), Suppl

Abstract

Pharmaceutical products are patient-oriented. If they had a deficient quality they might put live at risk. Ensuring their quality is not, however, a straightforward task and this is why different approaches have been used along the way. This article analyzes them and shows how our present approach, if well implemented, is very effective in ensuring quality.

Methods. This article analyzes the current pharmaceutical quality system as described by international guidances in the light of practical experience gathered by the author as an international GMP-consultant.

Result. Nowadays we have come to understand that as quality is a global concept in terms of time and of requirements, it has to be assured in a global way too. This is why quality assurance is a permanent process that starts during the development of a product and goes on during its manufacturing life. Manufacturing should be performed within a pharmaceutical quality system which ensures GMP compliance. Decisions should be science and risk-based. Products and processes are monitored by means of critical variables.

Conclusions. The approach followed in the 21st century for ensuring quality is very effective and allows for a progressive reduction of the level of quality risk. However, this quality system is either comprehensive or there is no quality

Author Biography

Jordi Botet, Glez. Tablas, 17, 5-1 08034 Barcelona Spain

GMP Compliance Consultant

References

Sterile drug products produced by aseptic processing – Current Good Manufacturing Practice. Guidance for Industry (2004). U.S. Department of Health and Human Services. Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Office of Regulatory Affairs (ORA). FDA, Rockville, MD, USA, 38. Available at: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070342.pdf

WHO Expert Committee on Specifications for Pharmaceutical Preparations. Good practices in the manufacture and quality control of drugs (1969). World Health Organisation (WHO). WHO, Geneva, Switzerland, 17–27. Available at: http://apps.who.int/iris/bitstream/10665/40736/1/WHO_TRS_418.pdf

Guideline on general principles of process validation. terile drug products produced by aseptic processing – Current Good Manufacturing Practice. Guidance for Industry (1987). Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Food and Drug Administration. Center for Devices and Radiological Health. FDA, Rockville, MD, USA.

Pharmaceutical CGMPS for the 21st century – A risk-based approach. Final report (2004). U.S. Food and Drug Administration (FDA). Available at: http://www.fda.gov

Process Validation: General Principles and Practices. Guidance for industry. Current Good Manufacturing Practices (CGMP) (2011). U.S. Department of Health and Human Services. Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Center for Veterinary Medicine (CVM). FDA, Rockville, MD, USA, 22. Available at: http://www.fda.gov/downloads/Drugs/.../Guidances/UCM070336.pdf

EU Guidelines to Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use. Vol. 4. (2015). European Commission. Directorate General for Health and Food Safety. European Commission, Brussels, Belgium, 16. Available at: http://ec.europa.eu/health/files/eudralex/vol-4/2015-10_annex15.pdf

Harmonised Tripartite Guideline. Pharmaceutical Quality System Q10 (2008). ICH, Geneva, Switzerland, 21. Available at: http://www.pmda.go.jp/files/000156592.pdf

Active Pharmaceutical Ingredients. Harmonised Tripartite Guideline Q7 (2000). ICH, Geneva, Switzerland, 49. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q7/Step4/Q7_Guideline.pdf

Development and manufacture of drug substances (chemical entities and biotechnological/biological entities). Harmonised Tripartite Guideline Q11 (2012). ICH, Geneva, Switzerland, 30. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q11/Q11_Step_4.pdf

The Rules Governing Medicinal Products in the European Union. Vol. 4. EU Guidelines to Good Manufacturing Practice. Medicinal Products for Human and Veterinary Use (2010). European Commission. Enterprise and Industry Directorate-General. Investigational Medicinal Products. European Commission, Brussels, Belgium, 19. Available at: http://ec.europa.eu/health/files/eudralex/vol-4/2009_06_annex13.pdf

Quality Risk Management Q9 (2005). ICH, Geneva, Switzerland, 23. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf

Harmonised Tripartite Guideline. Pharmaceutical development Q8(R2) (2009). ICH, Geneva, Switzerland, 28. Avaolable at: https://www.pmda.go.jp/files/000156835.pdf

WHO Expert Committee on Specifications for Pharmaceutical Preparations. WHO Good manufacturing practices for pharmaceutical products: main principles (2014). WHO, Geneva, Switzerland, 77–136. Available at: http://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/ISBN9789241209861-TRS986.pdf

Medicinal products for human and veterinary use. The rules governing medicinal products in the European Union. Vol. 4. European Commission. Good manufacturing practices. Brussels. Available at: http://ec.europa.eu

The Rules Governing Medicinal Products in the European Union. Vol. 4. EU Guidelines to Good Manufacturing Practice. Medicinal Products for Human and Veterinary Use (2015). European Commission. Enterprise Directorate-General. European Commission, Brussels, Belgium, 7. Available at: http://ec.europa.eu/health/human-use/quality/pc_quality/consultation_document_annex_17.pdf

Botet, J. (2015). Good Quality Practice (GQP) in Pharmaceutical Manufacturing: A Handbook. Bentham Science Publishers, Sharjah (U.A.E.), 503. doi: 10.2174/97816810811441150101

Downloads

Published

2016-01-29

Issue

Section

Pharmaceutical Sciences